Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on October 25, 2025
The Genome Frontier: How KFSHRC is Redefining the Future of Precision Medicine
RIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- When King Faisal Specialist Hospital and Research Centre (KFSHRC) first began large scale genomic testing a decade ago, the field of precision medicine was still in its infancy in the region. …
Beyond Gravity: How KFSHRC is Shaping the Future of Space Medicine
RIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- When Saudi research reached the International Space Station in 2023, it carried more than scientific instruments, it carried a vision of how medicine might evolve beyond Earth. For the first …
Inside the New KFSHRC Biobank: Building the Foundation for Healthier, Data Driven Future
ٍٍRIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- In the pursuit of better health outcomes, data has become medicine’s most valuable resource. At King Faisal Specialist Hospital and Research Centre in Riyadh, that principle now takes …
KFSHRC Enhances Brain Tumor Surgery Precision with Fluorescence-Guided Technology
JEDDAH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- For patients undergoing brain tumor surgery, precision can determine not only survival but also the preservation of vital functions such as speech, memory, and movement. At King Faisal …
Filling the Care Gap: How KFSHRC’s New Program Redefines Palliative Care for Young Lives
ٍٍRIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- Serious illness can be isolating at any age, but for adolescents and young adults, it often strikes at the most formative stages of life, when education, work, and identity are still taking …
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating …
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of …
Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025
Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages Broad mechanism of action of QEL- …
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with …
World Champion Marion Clignet’s Journey: One More Kilometer, 30 Years on the Road.
World Champion Marion Clignet’s Journey: One More Kilometer, 30 Years on the Road. Jelenew Unveils Marion Clignet’s Inspirational Journey in New Video Jelenew, the premium cycling apparel brand for women, proudly presents a powerful new video that …
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heartburn-free nights …
DeFi Crypto Mutuum Finance Completes Phase 1 Roadmap as V1 Protocol Launch Approaches
Dubai, UAE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- As the cryptocurrency market begins shifting its focus back to fundamentals, one new crypto project is standing out for its steady progress and structured delivery. Mutuum Finance (MUTM) has been methodically …
New Crypto Mutuum Finance (MUTM) Nears V1 Launch After Raising Over $17.8M
Dubai, UAE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- In a market where many blockchain projects promise innovation but struggle with execution, Mutuum Finance (MUTM) is quickly emerging as one of the top crypto demonstrating steady, measurable progress. The …
DebitMyData מספקת פתרון למשבר איסור היצוא העולמי של H20, חושפת את התפקיד הקריטי של Human Energy Grid
Human Energy Grid של DebitMyData פורט לודרדייל, פלורידה, Oct. 25, 2025 (GLOBE NEWSWIRE) -- DebitMyData™, Inc פרסמה עדכון חשוב עבור בעלי עניין גלובליים ולציבור הדיגיטלי בתגובה לאיסורי היצוא ובקרות הסחר האחרונות בהיבט של H20, המשפיעים על חדשנות בתחום הבינה …
Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
– 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd) – 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd) UTRECHT, Nederland en CAMBRIDGE, Massachusetts, Oct. 25, 2025 (GLOBE NEWSWIRE) -- …
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive …